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Background: Diabetes has been shown to negatively affect bone marrow structure and function resulting in reduced response to 
mobilizing stimuli and decreased numbers of circulating CD34+ cells. We evaluated the association of diabetes and insulin resistance with 
CD34+ cell mobilization and clinical response to cell therapy in patients with non-ischemic dilated cardiomyopathy (DCM).
methods: We enrolled 45 outpatients with DCM (NYHA III, LVEF<40%). All patients received granulocyte-colony stimulating factor (G-CSF; 
5 mg/kg, 5 days). CD34+ cell were then collected by apheresis and injected transendocardially. Twelve patients were diabetic (DM Group), 
17 had insulin resistance (IR Group), and 16 displayed normal glucose metabolism (No-IR Group).
results: After stimulation, we found significantly higher circulating numbers of CD34+ cells in IR Group (94±73x106 cells/L) than in No-IR 
Group (54±35x106 cells/L) or DM Group (31±20x106 cells/L, P=0.005). Consistent with this finding, apheresis yielded the highest numbers 
of CD34+ cell in IR group (IR Group: 216±110x106 cells; No-IR Group: 127±82x106 cells; DM Group: 77±83x106 cells, P=0.002). Six 
months after cell therapy we found an increase in LVEF in the IR Group (+5.6±6.9%) and the No-IR Group (+4.4±7.2%), but not in the DM 
Group (-0.9±5.4%, P=0.035). Furthermore, NT-proBNP levels decreased in both IR and No-IR groups, but not in the DM group (-606±850 
pg/ml; -698±1105 pg/ml; +238±963 pg/ml, P=0.034). Cell therapy had the highest relative efficacy in the No-IR group (26±26x106 cells 
required for every 1% increase in LVEF), reduced efficacy in the IR group (75±69x106 cells required for every 1% increase in LVEF), and 
induced no favorable response in the DM group.
conclusion:  Transendocardial therapy with CD34+ cells appears to be ineffective in DCM patients with diabetes. Insulin resistance is 
associated with improved CD34+ stem cell mobilization and preserved yet less efficient clinical response to cell therapy.
